http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021194865-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 |
| filingDate | 2021-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb5ac6eca188ecbb40174be2ea7b1dea http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8615f20a8e76c37e7c2fac2da0891e86 |
| publicationDate | 2021-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2021194865-A1 |
| titleOfInvention | Method for treating pneumonia, including covid-19 pneumonia, with an il6 antagonist |
| abstract | The application describes a method of treating pneumonia (e.g. COVID-19 pneumonia) in a patient comprising administering a weight-based intravenous dose of tocilizumab to the patient, wherein the weight-based dose is 8 mg/kg of tocilizumab. It also describes a method of treating pneumonia in a patient comprising administering an IL6 antagonist (e.g. an IL6 receptor antibody such as tocilizumab) to the patient in an amount effective to achieve a greater improvement in clinical outcome than standard of care (SOC) as measured on an ordinal scale of clinical status. Moreover, the application describes a method of treating pneumonia in a patient comprising: (a) administering a first weight-based 8 mg/ kg intravenous dose of tocilizumab to the patient; and (b) further comprising administering a second weight-based 8 mg/kg intravenous dose of tocilizumab to the patient 8-12 hours after the first dose, wherein the patient experiences no improvement or > one-category worsening on an ordinal scale of clinical status following the first dose. In addition, the application discloses a method of treating acute respiratory distress syndrome (ARDS) in a patient who does not have elevated IL6 level comprising administering an IL6 antagonist (e.g. an IL6 receptor antibody such as tocilizumab) to the patient. |
| priorityDate | 2020-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 444.